Challenges in improving influenza vaccine protection in the elderly

Expert Review of Vaccines

Volumn 10, Issue 1, 2011, Pages 7-11

  Petrovsky, Nikolai ^a   Ross, Ted M ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

adjuvant; elderly; immunosenescence; influenza; vaccine; virus

Indexed keywords

ADVAX; FLUBLOK; FP 01; GAMMAFLU; HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE; PROPIOLACTONE; UNCLASSIFIED DRUG;

ADULT; CELLULAR IMMUNITY; CROSS PROTECTION; DEVELOPED COUNTRY; HEMAGGLUTINATION INHIBITION TEST; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; MORBIDITY; MORTALITY; PNEUMONIA; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEASONAL INFLUENZA; T LYMPHOCYTE; VIRUS STRAIN;

AGE FACTORS; AGED; AGED, 80 AND OVER; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED;

EID: 78650441682     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.153     Document Type: Review

References (26)

1. Speizer FE, Horton S, Batt J, Slutsky AS. Respiratory diseases of adults. In: Disease Control Priorities in Developing Countries (2nd Edition). Jamison D, Breman J, Measham A et al. (Eds). Disease Control Priorities Project, World Bank, Washington, DC, USA, 681-693 (2006).
2. Falagas ME, Cholevas NV, Kapaskelis AM, Vouloumanou EK, Michalopoulos A, Rafailidis PI. Epidemiological aspects of 2009 H1N1 infuenza: the accumulating experience from the Northern Hemisphere. Eur. J. Clin. Microbiol. Infect. Dis. 29(11), 1327-1347 (2010).
3. Fiore AE, Uyeki TM, Broder K et al. Centers for Disease Control and Prevention (CDC). Prevention and control of infuenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8), 1-62 (2010).
4. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Effcacy and effectiveness of infuenza vaccines in elderly people: a systematic review. Lancet 366, 1165-1174 (2005). (Pubitemid 41393594)
5. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum hemagglutination-inhibiting antibody in protection against challenge infection with infuenza A2 and B viruses. J. Hyg. 70, 767-777 (1972).
6. Al-Khayatt R, Jennings R, Potter C W. Interpretation of responses and protective levels of antibody against attenuated infuenza A viruses using single radial haemolysis. J. Hyg. 93, 301-312 (1984).
7. Delem A. Serum SRH antibody level as a measure of the immunity against natural and artifcial A/Victoria/3/75 infections. Dev. Biol. Stand. 89, 391-396 (1977).
8. Gorse GJ, O'Connor TZ, Young SL et al. Effcacy trial of live, cold-adapted and inactivated infuenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 21, 2133-2144 (2003).
9. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology 120(4), 435-446 (2007).
10. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun. Ageing 4, 9 (2007).
11. Lord JM, Butcher S, Killampali V, Lascelles D, Salmon M. Neutrophil ageing and immunesenescence. Mech. Ageing Dev. 122(14), 1521-1535 (2001).
12. Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system. Curr. Opin Immunol. 17(5), 457-462 (2005).
13. Van Duin D, Shaw AC. Toll-like receptors in older adults. J. Am. Geriatr. Soc. 55(9), 1438-1444 (2007).
14. Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev. Mol. Med. 9(3), 1-17 (2007).
15. Goodwin K, Viboud C, Simonsen L. Antibody response to infuenza vaccination in the elderly: a quantitative review. Vaccine 24(8), 1159-1169 (2006).
16. Giudice GD, Hilbert AK, Bugarini R et al. An MF59-adjuvanted inactivated infuenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant infuenza virus strain A/Fujian/2002 than a subunit and a split infuenza vaccine. Vaccine 24, 3063-3065 (2006).
17. Sullivan SJ, Jacobson R, Poland GA. Advances in the vaccination of the elderly against infuenza: role of a high-dose vaccine. Expert Rev. Vaccines 9(10), 1127-1133 (2010).
18. Holland D, Booy R, De Looze F et al. Intradermal infuenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198, 650-658 (2008).
19. Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an infuenza challenge in a double-blind randomised placebo-controlled Phase 1b clinical trial. Vaccine 27(18), 2506-2512 (2009).
20. Glenn GM, Thomas DN, Poffenberger KL et al. Safety and immunogenicity of an infuenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 27(Suppl. 6), G60-G66 (2009).
21. Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix infuenza vaccine. Vaccine 22(23-24), 3136-3143 (2004).
22. Mbawuike I, Zang Y, Couch RB. Humoral and cell-mediated immune responses of humans to inactivated infuenza vaccine with or without QS21 adjuvant. Vaccine 25(17), 3263-3269 (2007).
23. Lobigs M, Pavy M, Hall RA et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralising antibody against homologous and heterologous faviviruses. J. Gen. Virol. 91, 1407-1417 (2010).
24. Petrovsky N. Lessons learned from the H1N1 2009 pandemic. Hum. Vaccin. 6(10), 1-4 (2010).
25. Müllbacher A, Ada GL, Hla RT. g-irradiated infuenza A virus can prime for a cross-reactive and cross-protective immune response against infuenza A viruses. Immunol. Cell. Biol. 66(Pt 2), 153-157 (1988).
26. Treanor JJ, Taylor DN, Tussey L et al. Safety and immunogenicity of a recombinant hemagglutinin infuenza-fagellin fusion vaccine (VAX125) in healthy young adults. Vaccine DOI: 10.1016/j.vaccine.2010.10.009 (2010) (Epub ahead of print).